Dalvance launch underway

|By:, SA News Editor

Durata Therapeutics' (DRTX +0.8%) Dalvance (dalbavancin) is now available in the U.S. as a treatment for adult patients with acute bacterial skin and skin structure infections ((ABSSSI)). The company began shipping the antibiotic to distributors this week.

The FDA approved Dalvance on May 23 as a Qualified Infectious Disease Product.